A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita

Completed · Phase 3

Conditions studied: Pachyonychia Congenita

In brief

This study evaluates the safety and efficacy of QTORIN 3.9% rapamycin anhydrous gel in the treatment of adults with Pachyonychia Congenita. This study includes a screening period, baseline period and 6-month treatment period.

Key facts

Study ID

NCT05180708

Run by

Palvella Therapeutics, Inc.

People needed

87

Starts

2021-11-29

Expected to finish

2023-06-30

Last updated by the study team

2024-08-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Stanford University — Palo Alto, California, United States
• Yale University — New Haven, Connecticut, United States
• Park Avenue Dermatology — Orange Park, Florida, United States
• Minnesota Clinical Study Center — Fridley, Minnesota, United States
• Oregon Health and Sciences University — Portland, Oregon, United States
• DermResearch, Inc. — Austin, Texas, United States
• University of Utah — Murray, Utah, United States
• Royal London Hospital — London, Whitechapel, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.